In August 2024, we were thrilled to host UK-based Professor Dean Fennell, a renowned expert in mesothelioma research, in Sydney.  He has designed and led numerous investigator-initiated trials from phase 1 through phase 3, placing him at the forefront of this critical field.

Join James O’Loghlin as he engages in a thought-provoking discussion with Professor Fennell about his clinical and translational research in mesothelioma, as well as the latest treatment options available in the UK.

In this episode, you’ll discover:

• Insights into Professor Fennell’s groundbreaking research on the gut microbiome and its influence on treatment response.


• How genetic discoveries are shaping precision medicine and personalised therapy for mesothelioma.


• An overview of the clinical trials he’s spearheading and the significant advancements in this area.

Professor Fennell also shares details about the exciting collaborations between the UK and ADDRI in Australia, exploring the potential for simultaneous clinical trials in both countries to better serve patients.

His optimism about new therapeutic developments and the commitment to global collaboration shines through, making this a must-listen episode for anyone interested in the future of mesothelioma treatment.

You can find out more about Professor Dean Fennell’s work here: https://mesothelioma-research-leicester.com/team/dean-fennell/

To find out more about ADDRI, visit our website: www.addri.org.au

Thank you to our Podcast Interviewer and host James O’Loghlin and Producer Rod Morri from Sydney Podcast Studios https://sydneypodcaststudios.com.au/

If you have any questions or comments, please email info@addri.org.au